Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
7,089 press releases indexed under healthcare.
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
(PR-inside.com) Clearance Covers Software Enhancements for Greater Patient Flexibility and Pivot Customization SAN DIEGO, CA / ACCESS Newswire / September 3, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, today announced that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system's functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades. "We are pleased that this ..
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology...
Toronto, Ontario--(Newsfile Corp. - September 3, 2026) - AVANT, the premium private fitness and wellness club, and Health In A Box® today announced a partnership that brings physician-led preventive health programs to AVANT members beginning in mid-September.Members receive biomarker testing, clinical interpretation, and a personalized health action plan built with a clinical team of physicians and naturopathic doctors. Clinical review and follow-up are delivered virtually. AVANT's personal...
Clearance Covers Software Enhancements for Greater Patient Flexibility and Pivot Customization
LOS ÁNGELES, 3 de septiembre de 2026 /PRNewswire-HISPANIC PR WIRE/ -- Randall v. United Network for Organ Sharing, et al., caso n.º 2:23-cv-02576-MEMF-MAA, Tribunal de Distrito de los EE. UU. para el Distrito Central de California ¿De qué trata la demanda? Las personas que presentaron la...
CARMEL, Ind., Sept. 3, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today that, in partnership...
Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of the Pulmonary...
STAMFORD, Conn., Sept. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today announced that members of Curaleaf's executive management team will be participating in the...
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European UnionThe Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emergeRhelion intends to leverage Filament's...
Agreement expands support for Canadian healthcare professionals and families impacted by Dravet syndrome BLAINVILLE, QC, Sept. 3, 2026 /PRNewswire/ -- Médunik Canada, a Canadian owned and operated pharmaceutical company dedicated to improving the health and quality of life of people...
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: